Literature DB >> 19387765

Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

K P Ng1, F Ramos, S M Sultan, D A Isenberg.   

Abstract

This study aims to report the concomitant diseases observed and damage outcome in a cohort of patients with adult idiopathic inflammatory myositis (IIM) during long-term follow-up. All patients with IIM were identified from a single centre (follow-up between 1979 and 2006) and fulfilled at least three of the four Bohan and Peter criteria. Patients with inclusion body myositis, juvenile-onset myositis and overt overlap syndromes were excluded. Medical notes were retrospectively reviewed. Concomitant diseases identified were divided into 12 different organ systems (bone, cardiac, respiratory, gastrointestinal, renal, central nervous, malignancy, infection, endocrine, eyes, dermatological and haematological). Patient damage index was calculated using the Myositis Damage Index tool. Fifty-five patients (31 polymyositis, 24 dermatomyositis) were identified. The most prevalent organ system involved was lung with 40 events per 1,000 patient years follow-up. There was significant steroid-related complications with 17/18 patients with bone involvement having osteopenia/osteoporosis. Sjogren's syndrome (n = 3) was the most frequent concomitant auto-immune disease observed. Patients with a higher number of organ systems involved had a significantly higher damage index (r = 0.48, p = 0.001). White patients showed a significant trend to develop more than three other organ system involvement (p < 0.0001) and myositis-related lung disease (p < 0.0001) compared to other races. There is significant steroid-related morbidity in adult IIM patients under long-term follow-up. The prevalence of another concomitant auto-immune disease unlike patients with lupus or Sjogren's syndrome is low.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387765     DOI: 10.1007/s10067-009-1181-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.

Authors:  I Marie; E Hachulla; P Y Hatron; M F Hellot; H Levesque; B Devulder; H Courtois
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

3.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

4.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

Review 5.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

6.  Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy.

Authors:  Manuelle Viguier; Sébastien Fouéré; Pauline de la Salmonière; Claire Rabian; Céleste Lebbe; Louis Dubertret; Patrice Morel; Hervé Bachelez
Journal:  Medicine (Baltimore)       Date:  2003-03       Impact factor: 1.889

7.  Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis.

Authors:  Ejaz A Shamim; Lisa G Rider; Janardan P Pandey; Terrance P O'Hanlon; Luis J Jara; Eduardo A Samayoa; Ruben Burgos-Vargas; Janitzia Vazquez-Mellado; Jorge Alcocer-Varela; Mario Salazar-Paramo; Abraham Garcia Kutzbach; James D Malley; Ira N Targoff; Ignacio Garcia-De la Torre; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2002-07

8.  Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis.

Authors:  A Ponyi; G Borgulya; T Constantin; A Váncsa; L Gergely; K Dankó
Journal:  Rheumatology (Oxford)       Date:  2004-09-20       Impact factor: 7.580

9.  Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.

Authors:  K E Tymms; J Webb
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  12 in total

1.  Diagnosis and treatment of the idiopathic inflammatory myopathies.

Authors:  David J Gazeley; Mary E Cronin
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-12       Impact factor: 5.346

Review 2.  Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.

Authors:  Beatriz Y Hanaoka; Charlotte A Peterson; Craig Horbinski; Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2012-06-12       Impact factor: 20.543

3.  [Clinical and immunological characteristics of 88 cases of overlap myositis].

Authors:  Y S Xiao; F Y Zhu; L Luo; X Y Xing; Y H Li; X W Zhang; D H Shen
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

4.  Perspectives on glucocorticoid usage in patients with adult inflammatory myopathy.

Authors:  Jesús Loarce-Martos; James B Lilleker; Eve Alder; Jo Goode; Hector Chinoy
Journal:  Clin Rheumatol       Date:  2021-06-29       Impact factor: 2.980

5.  Trends in dermatomyositis- and polymyositis-related mortality in the state of São Paulo, Brazil, 1985-2007: multiple cause-of-death analysis.

Authors:  Augusto H Santo; José Maria P Souza; Celso E Pinheiro; Deborah Cc Souza; Emilia I Sato
Journal:  BMC Public Health       Date:  2010-10-11       Impact factor: 3.295

6.  Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.

Authors:  Xiao Ming Shu; Xin Lu; Yao Xie; Guo Chun Wang
Journal:  BMC Neurol       Date:  2011-11-09       Impact factor: 2.474

7.  Overlap between dermatomyositis and ANCA vasculitides.

Authors:  Claudia Yuste; Molefe Rapalai; Benjamin A Pritchard; Terence J Jones; Constanza Amoasii; Atheer Al-Ansari; Satish B Ramakrishna
Journal:  Clin Kidney J       Date:  2013-12-23

8.  Risk factors for osteoporosis, falls and fractures in hereditary myopathies and sporadic inclusion body myositis - A cross sectional survey.

Authors:  F Danckworth; N Karabul; A Posa; F Hanisch
Journal:  Mol Genet Metab Rep       Date:  2014-02-11

Review 9.  Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management.

Authors:  Anett Vincze; János Gaál; Zoltán Griger
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

10.  Increased prevalence of celiac disease in idiopathic inflammatory myopathies.

Authors:  Olof Danielsson; Björn Lindvall; Claes Hallert; Magnus Vrethem; Charlotte Dahle
Journal:  Brain Behav       Date:  2017-09-05       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.